Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465751 | 1.00 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL29465744 | 0.91 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL22772870 | 0.91 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL22772818 | 0.88 | GRIN2B (0.85) | GRIN2B | |
| SCHEMBL30952100 | 0.88 | GRIN2B (0.85) | GRIN2B | |
| SCHEMBL22772872 | 0.86 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL29465718 | 0.86 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL22772862 | 0.86 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL29465722 | 0.86 | GRIN2B (1.00) | GRIN2B | |
| SCHEMBL22772886 | 0.85 | GRIN2B (1.00) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315590-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | claimed |
| EP-3983413-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | claimed |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | claimed |
| WO-2020249802-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | claimed |
| US-20200392113-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | claimed |
| US-11993587-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-28 | — | — | US | disclosed |
| US-20220315590-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| EP-3983413-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2022-04-20 | — | — | EP | disclosed |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| WO-2020249802-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249802-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392113-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
| US-20200392113-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885 |
| US-20200392113-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885 |
| US-20220315590-A1 | SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885 |
| US-11993587-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.